Caribou Biosciences, Inc. (CRBU) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies using its CRISPR genome-editing platform. The company has no approved products and generates revenue primarily through licensing and collaboration agreements.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Licensing & Collaboration Revenue | $2,024 | $23,662 | $7,917 | $30,919 |
| Net Loss | $(34,684) | $(10,002) | $(113,615) | $(67,565) |
| Loss Per Share (Basic/Diluted) | $(0.38) | $(0.12) | $(1.26) | $(0.98) |
| Operating Expenses (Total) | $40,262 | $38,295 | $135,658 | $109,536 |
| Cash & Cash Equivalents | $31,970 | $51,162 | $31,970 | $51,162 |
| Marketable Securities | $249,045 | $321,242 | $249,045 | $321,242 |
| Total Liquidity (Cash + Securities) | $281,015 | $372,404 | $281,015 | $372,404 |
| Accumulated Deficit | $(412,900) | $(264,780) | $(412,900) | $(264,780) |
Note: The filing does not provide specific gross margin or operating margin percentages due to the nature of the business model (licensing revenue vs. R&D heavy expenses).
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped significantly in Q3 2024 ($2.0M) compared to Q3 2023 ($23.7M). This is primarily due to the termination of the AbbVie collaboration agreement in October 2023, which generated $21.5M in revenue in the prior year's quarter. No revenue was recognized from AbbVie in 2024.
- Increased Net Loss: The net loss widened to $34.7M in Q3 2024 from $10.0M in Q3 2023, driven by the revenue drop and increased operating expenses.
- Operating Expenses: Research and Development (R&D) expenses increased to $30.4M in Q3 2024 from $28.6M in Q3 2023. This increase was driven by higher external CRO/CMO costs for clinical trials and personnel-related expenses, including severance costs from a workforce reduction.
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from $372.4M at year-end 2023 to $281.0M as of September 30, 2024, reflecting a net cash burn of $102.7M from operating activities over the nine-month period.
Guidance, Outlook, and Risks
- Cash Runway: Management expects existing liquidity ($281.0M) to fund operations for at least the next 12 months. A workforce reduction of 12% (21 positions) announced in July 2024 is expected to extend the cash runway by at least six months into the second half of 2026.
- Clinical Pipeline:
- CB-010 (Anti-CD19 CAR-T): Dose expansion in ANTLER trial ongoing. Data from partial HLA matching cohorts expected in H1 2025. Pivotal Phase 3 trial initiation expected in H2 2025. Expanding into autoimmune diseases (GALLOP trial) by year-end 2024.
- CB-011 (Anti-BCMA CAR-T): Dose escalation in CaMMouflage trial ongoing. Initial data expected H1 2025.
- CB-012 (Anti-CLL-1 CAR-T): Dose escalation in AMpLify trial ongoing.
- Restructuring: The company discontinued its allogeneic CAR-NK platform and recorded $0.6M in non-recurring restructuring charges in Q3 2024.
- Legal Contingency: A securities class action lawsuit (Bergman v. Caribou Biosciences) was settled in principle for $3.9M. The settlement was preliminarily approved by the court in October 2024, with a final hearing scheduled for February 2025. The liability is accrued in current liabilities.
- Risks: The company faces risks related to the success of clinical trials, regulatory approval, ability to raise additional capital, and potential dilution from future equity offerings.
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of revenue streams post-AbbVie termination. Current revenue is heavily reliant on related parties (Pfizer, Edge Animal Health) and smaller licensees.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the stated 12-month runway. The company burned ~$103M in cash from operations in the first nine months of 2024.
- Clinical Milestones: Track the timing and results of the CB-010 partial HLA matching data (expected H1 2025) and the initiation of the pivotal Phase 3 trial (expected H2 2025), as these are critical for future valuation and funding.
- Legal Settlement: Confirm the final court approval of the $3.9M securities litigation settlement and ensure no additional legal liabilities arise.
- Capital Raising: Assess the company's ability to raise capital via its At-The-Market (ATM) program or other equity offerings if the cash runway shortens due to clinical trial costs.